Impact Therapeutics, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nanjing China (2009)

Organization Overview

First Clinical Trial
2017
NCT03507543
First Marketed Drug
2019
fedratinib (Inrebic)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

IMPACT | Impact Biotech Ltd | Impact Therapeutics, Inc.

Active Ingredients

Marketed Drugs (1)

fedratinib (Inrebic) (2019)

Drugs in Phase 3 Trials (1)

imp4927 (1 trial)

Drugs in Phase 2 Trials (1)

Senaparib (11 trials)

Drugs in Phase 1 Trials (3)

imp7068 (1 trial)

imp9064 (1 trial)

padeliporfin (Tookad) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Lung Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 1)

Small Cell Lung Carcinoma (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 5